


PERSPECTIVES OF INDIAN MEDICINAL PLANTS IN THE MANAGEMENT OF DIABETES MELLITUS (2014)



Contents

Foreword

Preface

Acknowledgements

Abbreviations

Introduction to the Book

1. **AYURVEDIC AND UNANI CONCEPTS OF PATHOGENESIS AND TREATMENT OF DIABETES MELLITUS**

1.1 Brief Introduction to Ayurveda

1.2 Classification and Pathogenesis of *Prameha*

1.2.1 Introductory remarks

1.2.2 The predisposing factors

1.2.3 Classification of *Prameha*

1.2.3.1 Etiological classification

1.2.3.2 Clinical classification

1.2.3.3 Prognostic classification

- 1.2.4 Pathogenesis of *Prameha*
- 1.3 Treatment of *Prameha*
 - 1.3.1 Diet
 - 1.3.2 Life style changes
 - 1.3.3 Therapeutic interventions
 - 1.3.3.1 *Sakṣsodhana*
 - 1.3.3.2 Drugs
 - 1.3.3.3 Management of complications
- 1.4 Basic Concepts of Unānī Medicine
 - 1.4.1 *Arkān*
 - 1.4.2 *Mizāj*
 - 1.4.3 *Akhlāt*
 - 1.4.4 *Aza*
 - 1.4.5 *Ruh*
 - 1.4.6 *Quwā*
 - 1.4.7 *Afal*
 - 1.4.8 Concluding remarks
- 1.5 Classification, Pathogenesis and Treatment of Zibetus
 - 1.5.1 Classification
 - 1.5.1.1 Zibetus sada/barid
 - 1.5.1.2 Zibetus sukkari/har
 - 1.5.2 Pathogenesis
 - 1.5.3 Treatment
 - 1.5.3.1 Diet
 - 1.5.3.2 Exercise and rest
 - 1.5.3.3 Drugs

References

2. MODERN CONCEPTS OF PATHOGENESIS AND TREATMENT OF DIABETES MELLITUS

- 2.1 Classification and Diagnostic Criteria of Diabetes Mellitus

- 2.1.1 Classification of diabetes mellitus
- 2.1.2 Pathogenesis of diabetes mellitus
 - 2.1.2.1 Type 1 diabetes (T1DM)
 - 2.1.2.2 Type 2 diabetes (T2DM)
 - 2.1.2.3 Diabetes in children and youth
 - 2.1.2.4 Type 2 diabetes and the metabolic syndrome
 - 2.1.2.5 Maturity onset diabetes of the young (MODY)
 - 2.1.2.6 Gestational diabetes mellitus (GDM)
- 2.1.3 Genetic aspects of type 2 diabetes
- 2.1.4 Current diagnostic criteria and their prognostic value
(Impact on outcome and management)
- 2.2 Complications of Diabetes and their Pathogenesis
 - 2.2.1 Acute complications
 - 2.2.2 Chronic complications
 - 2.2.2.1 Cardiovascular complications
 - 2.2.2.2 Hypertension
 - 2.2.2.3 Lower extremity complications
 - 2.2.2.4 Diabetic retinopathy
 - 2.2.2.5 Neuropathy
 - 2.2.2.6 Nephropathy
 - 2.2.2.7 Infections
 - 2.2.2.8 Gastrointestinal/genitourinary dysfunction
 - 2.2.2.9 Dermatologic manifestations
 - 2.2.3 Mechanisms of hyperglycaemia-induced damage
 - 2.2.3.1 Aldose reductase
 - 2.2.3.2 Advanced glycation end products (AGEs)
 - 2.2.3.3 Diacylglycerol (DAG) and protein kinase C (PKC)
 - 2.2.3.4 Increased hexosamine pathway flux
 - 2.2.3.5 Increased oxidative stress
 - 2.2.4 Hypoglycaemia
- 2.3 Insulin Resistance and its Sequelae

- 2.3.1 Insulin resistance
 - 2.3.1.1 Mutations in genes encoding insulin receptor and insulin receptor substrate
- 2.3.2 Syndromes associated with insulin resistance
 - 2.3.2.1 Acanthosis nigricans
 - 2.3.2.2 Ovarian hyperandrogenism and polycystic ovary syndrome (PCOS)
 - 2.3.2.3 Abnormal glucose tolerance
 - 2.3.2.4 Leprechaunism and the Rabson-Mendenhall syndrome
 - 2.3.2.5 Autoimmune-insulin resistance
- 2.3.3 Approaches towards treatment of insulin resistance
- 2.4 Management of Diabetes
 - 2.4.1 Prevention strategies
 - 2.4.1.1 Dietary regulation
 - 2.4.1.2 Role of exercise
 - 2.4.2 Drugs used for treatment of diabetes mellitus
 - 2.4.2.1 Insulin and its analogues
 - 2.4.2.2 Insulin secretagogues
 - 2.4.2.3 Agents reducing insulin resistance
 - 2.4.2.4 α -Glucosidase inhibitors
 - 2.4.2.5 Other potential antidiabetic agents
 - 2.4.2.6 Adding oral agents to insulin therapy
 - 2.4.2.7 Gene therapy of type 1 diabetes
 - 2.4.2.8 Islet transplantation in type 1 diabetic patients
 - 2.4.2.9 Stem cell therapy
 - 2.4.2.10 Drugs for treatment of complications of diabetes

References

3. INDIAN PLANTS INVESTIGATED FOR ANTIDIABETIC ACTIVITY

- 3.1 Plants Used in Ayurvedic Formulations for Treatment of Diabetes

- 3.2 Plants Used in Siddha System for Treatment of Diabetes
- 3.3 Plants Used in Unani Formulations for Treatment of Diabetes
- 3.4 Plants Screened for Antidiabetic Activity
- 3.5 Other Indian Studies on Natural Products with Antidiabetic Potential
 - 3.5.1 Historical
 - 3.5.2 Plants with hypoglycaemic activity
 - 3.5.3 Plants effective in complications of diabetes
 - 3.5.3.1 Effect on ocular complications
 - 3.5.3.2 Effect on other complications
 - 3.5.4 Plants reported active in ethnomedical surveys
 - 3.5.5 Marine flora and fauna

References

4. PROMISING LEADS FROM INDIAN PLANTS FOR ANTIDIABETIC ACTIVITY

- 4.1 *Aegle marmelos* (Linn.) Correa
 - 4.1.1 Other names
 - 4.1.2 Part used
 - 4.1.3 Botanical description and habitat
 - 4.1.4 Adulterants/Substitutes
 - 4.1.5 Ayurvedic description and properties
 - 4.1.6 Chemical constituents
 - 4.1.7 Standardization and quality control
 - 4.1.8 Antidiabetic activity
 - 4.1.9 Other pharmacological actions
 - 4.1.10 Other clinical studies
 - 4.1.11 Safety studies
 - 4.1.12 Classical dosage
 - 4.1.13 Classical Ayurvedic/Unāni formulations containing
A. marmelos
 - 4.1.14 Future prospects

References

- 4.2 *Allium cepa* Linn.
 - 4.2.1 Other names
 - 4.2.2 Part used
 - 4.2.3 Botanical description and habitat
 - 4.2.4 Adulterants/Substitutes
 - 4.2.5 Ayurvedic description and properties
 - 4.2.6 Chemical constituents
 - 4.2.7 Standardization and quality control
 - 4.2.8 Antidiabetic activity
 - 4.2.9 Other pharmacological actions
 - 4.2.10 Other clinical studies
 - 4.2.11 Safety studies
 - 4.2.12 Classical dosage
 - 4.2.13 Future prospects

References

- 4.3 *Allium sativum* Linn.
 - 4.3.1 Other names
 - 4.3.2 Part used
 - 4.3.3 Botanical description and habitat
 - 4.3.4 Adulterants/Substitutes
 - 4.3.5 Ayurvedic description and properties
 - 4.3.6 Chemical constituents
 - 4.3.7 Standardization and quality control
 - 4.3.8 Antidiabetic activity
 - 4.3.9 Other pharmacological actions
 - 4.3.10 Other clinical studies
 - 4.3.11 Safety studies
 - 4.3.12 Future prospects

References

- 4.4 *Azadirachta indica* A. Juss.

- 4.4.1 Other names
- 4.4.2 Part used
- 4.4.3 Botanical description and habitat
- 4.4.4 Adulterants/Substitutes
- 4.4.5 Ayurvedic description and properties
- 4.4.6 Chemical constituents
- 4.4.7 Standardization and quality control
- 4.4.8 Antidiabetic activity
- 4.4.9 Other pharmacological actions
- 4.4.10 Other clinical studies
- 4.4.11 Safety studies
- 4.4.12 Classical dosage
- 4.4.13 Classical Ayurvedic/Unānī formulations containing *A.indica*
- 4.4.14 Future prospects

References

- 4.5 *Ficus benghalensis* Linn.
 - 4.5.1 Other names
 - 4.5.2 Part used
 - 4.5.3 Botanical description and habitat
 - 4.5.4 Ayurvedic description and properties
 - 4.5.5 Traditional uses
 - 4.5.6 Chemical constituents
 - 4.5.7 Standardization and quality control
 - 4.5.8 Antidiabetic activity
 - 4.5.9 Other pharmacological actions
 - 4.5.10 Safety studies
 - 4.5.11 Classical dosage
 - 4.5.12 Classical Ayurvedic/Unānī formulations containing
F. benghalensis
 - 4.5.13 Future prospects

References

- 4.6 *Ficus religiosa* Linn.
 - 4.6.1 Other names
 - 4.6.2 Part used
 - 4.6.3 Botanical description and habitat
 - 4.6.4 Adulterants/Substitutes
 - 4.6.5 Ayurvedic description and properties
 - 4.6.6 Chemical constituents
 - 4.6.7 Standardization and quality control
 - 4.6.8 Antidiabetic activity
 - 4.6.9 Other pharmacological actions
 - 4.6.10 Safety studies
 - 4.6.11 Classical dosage
 - 4.6.12 Classical Ayurvedic/Unānī formulations containing
F. religiosa
 - 4.6.13 Future prospects

References

- 4.7 *Gymnema sylvestre* (Retz.) Schult.
 - 4.7.1 Other names
 - 4.7.2 Part used
 - 4.7.3 Botanical description and habitat
 - 4.7.4 Ayurvedic description and properties
 - 4.7.5 Traditional uses
 - 4.7.6 Chemical constituents
 - 4.7.7 Standardization and quality control
 - 4.7.8 Antidiabetic activity
 - 4.7.9 Sweetness inhibitory activity
 - 4.7.10 Other pharmacological actions
 - 4.7.11 Safety studies
 - 4.7.12 Classical dosage
 - 4.7.13 Classical Ayurvedic/Unānī formulations containing
G. sylvestre

4.7.14 Future prospects

References

- 4.8 *Momordica charantia* Linn.
 - 4.8.1 Other names
 - 4.8.2 Part used
 - 4.8.3 Botanical description and habitat
 - 4.8.4 Adulterants/Substitutes
 - 4.8.5 Ayurvedic description and properties
 - 4.8.6 Chemical constituents
 - 4.8.7 Standardization and quality control
 - 4.8.8 Antidiabetic activity
 - 4.8.9 Other pharmacological actions
 - 4.8.10 Other clinical studies
 - 4.8.11 Safety studies
 - 4.8.12 Classical dosage
 - 4.8.13 Future prospects

References

- 4.9 *Pterocarpus marsupium* Roxb.
 - 4.9.1 Other names
 - 4.9.2 Part used
 - 4.9.3 Botanical description and habitat
 - 4.9.4 Adulterants/Substitutes
 - 4.9.5 Ayurvedic description and properties
 - 4.9.6 Chemical constituents
 - 4.9.7 Standardization and quality control
 - 4.9.8 Antidiabetic activity
 - 4.9.9 Other pharmacological actions
 - 4.9.10 Other clinical studies
 - 4.9.11 Safety studies
 - 4.9.12 Classical dosage
 - 4.9.13 Classical Ayurvedic/Unāni formulations containing

P. marsupium

4.9.14 Future prospects

References

4.10 *Swertia chirayita* (Roxb. ex Flem.) H. Karst.

4.10.1 Other names

4.10.2 Part used

4.10.3 Botanical description and habitat

4.10.4 Adulterants/Substitutes

4.10.5 Ayurvedic description and properties

4.10.6 Chemical constituents

4.10.7 Standardization and quality control

4.10.8 Antidiabetic activity

4.10.9 Other pharmacological actions

4.10.10 Safety studies

4.10.11 Classical dosage

4.10.12 Classical Ayurvedic/Unāni formulations containing
S. chirayita

4.10.13 Future prospects

References

4.11 *Syzygium cumini* (Linn.) Skeels

4.11.1 Other names

4.11.2 Part used

4.11.3 Botanical description and habitat

4.11.4 Ayurvedic description and properties

4.11.5 Traditional uses

4.11.6 Chemical constituents

4.11.7 Standardization and quality control

4.11.8 Antidiabetic activity

4.11.9 Other pharmacological actions

4.11.10 Safety studies

4.11.11 Classical dosage

4.11.12 Classical Ayurvedic/Unāni formulations containing
S. cumini

4.11.13 Future prospects

References

4.12 *Trigonella foenum-graecum* Linn.

4.12.1 Other names

4.12.2 Part used

4.12.3 Botanical description and habitat

4.12.4 Ayurvedic description and properties

4.12.5 Chemical constituents

4.12.6 Standardization and quality control

4.12.7 Antidiabetic activity

4.12.8 Other pharmacological actions

4.12.9 Other clinical studies

4.12.10 Safety studies

4.12.11 Classical dosage

4.12.12 Classical Ayurvedic/Unāni formulations containing
T. foenum-graecum

4.11.13 Future prospects

References

5. NEW TARGETS AND SCREENING PROCEDURES

5.1 New Drug Targets for Diabetes

5.1.1 Hepatic glucose production

5.1.2 β -Cells of pancreas

5.1.3 Insulin signalling pathways

5.1.4 Lipid metabolism

5.1.5 Some newer targets

5.1.6 Concluding remarks

5.2 Animal Models for Studies on Diabetes

- 5.2.1 Pancreatectomy
- 5.2.2 Chemically induced diabetes
- 5.2.3 Genetic models of diabetes
- 5.2.4 Knockout models
 - 5.2.4.1 Models to study insulin action
 - 5.2.4.2 Animal models to study insulin secretion
- 5.2.5 Other animal models
- 5.2.6 Models for studying secondary complications

References

6. DISCUSSION AND FUTURE APPROACH

7. SUMMARY

INDICES

- | | |
|-----------|----------------------------------|
| Index I | Botanical names |
| Index II | Chemical constituents |
| Index III | Classical Ayurvedic formulations |
| Index IV | Classical Unāni formulations |
| Index V | Other names of the plants |